Vanda Pharmaceuticals Inc. business relationships

Companies named in Vanda Pharmaceuticals Inc.’s 10-K filed 2026-02-12, and public companies whose annual reports name Vanda Pharmaceuticals Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 70 / 100
Agent readiness: 0 / 100
AI adoption: - / 100

Named in Vanda Pharmaceuticals Inc.’s annual report 6

BRISTOL MYERS SQUIBB CO (BMY)Licensor7.7
“As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $ 8.0 million to BMS.” SEC filing
NOVARTIS AG (NVS)Licensor7.7
“License Agreement, dated December 22, 2014, by and between Novartis Pharma AG and the registrant (relating to AQW051) (filed as Exhibit 10.62 to the registrant's annual report on Form 10-K (File No. 001-34186) on March 13, 2015 and incorporated herein by reference).” SEC filing
Sanofi (SNY)Customer6.7
“We paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing know-how.” SEC filing
ELI LILLY & Co (LLY)Licensor6.6
“As a result of this approval, the Company met a milestone under its license agreement with Eli Lilly and Company (Lilly) that required the Company to make a license payment of $ 10.0 million to Lilly, which was accrued in the Company's Consolidated Balance Sheets as of December 31, 2025 and represen...” SEC filing
MSN Laboratories Private LimitedLicensor4.7
“License Agreement, dated January 13, 2022, by and among MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, Impax Laboratories LLC and the registrant (filed as Exhibit 10.1 to the registrant's quarterly report on Form 10-Q (File No. 001-34186) on May 6, 2022 and incorporated herein by refere...” SEC filing
OliPass CorporationPartner4.2
“In 2022, we announced a research and development collaboration agreement with OliPass Corporation (OliPass) to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids.” SEC filing

Companies whose annual reports name Vanda Pharmaceuticals Inc. 2

ANAPTYSBIO, INC (ANAB)names it as licensor4.7
“Exclusive License Agreement, dated January 31, 2025, by and between the Company and Vanda Pharmaceuticals Inc.” SEC filing
ANAPTYSBIO, INC (ANAB)names it as partner4.7
“We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist ( Jemperli (dostarlimab-gxly) or " Jemperli ") to GSK and an IL-36R antagonist ("Quimilza") to Vanda Pharmaceuticals Inc. ("Vanda").” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.